Related Experiment Videos
Activated protein C: more effective than nonactivated protein C?
Critical Care Medicine
|May 29, 2003
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial.
The journal of allergy and clinical immunology. Global·2023
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension.
The lancet. Gastroenterology & hepatology·2022
Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects.
The Journal of antimicrobial chemotherapy·2016
Mechanistic Specificity of Capillary Leak Indices: Validation in Heart Failure as a Negative Control.
Critical care medicine·2026
A 1-Hour Resuscitation Bundle for Prehospital Management of Septic Shock.
Critical care medicine·2026
Comparative safety of PICC-ports and chest ports in oncology: A monocentric retrospective cohort study.
The journal of vascular access·2026
Combinatorial effects of curcumin, morin, and phyllanthin in MDA-MB-231 and MCF-7 breast cancer cell lines.
Indian journal of pharmacology·2026
Local Therapy for Isolated Residual Metastatic Melanoma and Renal Cell Carcinoma Following Immune Checkpoint Inhibition Leading to Long-Term Remission.
Journal of immunotherapy (Hagerstown, Md. : 1997)·2026
Cost-effectiveness analysis of liposomal Irinotecan in combination with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas in Greece.
Expert review of pharmacoeconomics & outcomes research·2026